Annals of the Russian academy of medical sciencesAnnals of the Russian academy of medical sciencesВестник Российской академии медицинских наук0869-60472414-3545"Paediatrician" Publishers LLC23010.15690/vramn.v67i12.475IMMUNOLOGY: CURRENT ISSUESАКТУАЛЬНЫЕ ВОПРОСЫ ИММУНОЛОГИИCLINICAL AND EXPERIMENTAL RESEARCH OF IMMUNOMODULATORY EFFECT OF AMISULPRIDEКЛИНИКО-ЭКСПЕРИМЕНАЛЬНЫЕ ИССЛЕДОВАНИЯ ИММУНОМОДУЛИРУЮЩЕГО ЭФФЕКТА АМИСУЛЬПРИДАVetluginaT. P.ВетлугинаТ. П.
Russian Federation

PhD, Professor, Head of Laboratory of Clinical Psychoneuroimmunology, Federal State Budget Institution Scientific Research Institute of Physical Health, Siberian Department, Russian Academy of Medical Sciences. Address: 634014, Tomsk, Aleutskaya str. 4; Tel.: (3822) 72-44-15

vetlug@mail.tomsknet.ruLobachevaO. A.ЛобачеваО. А.
Russian Federation

PhD, Leading Scientific Worker, Laboratory of Clinical Psychoneuroimmunology, Federal State Budget Institution Scientific Research Institute of Physical Health, Siberian Department, Russian Academy of Medical Sciences. Address: 634014, Tomsk, Aleutskaya str. 4; Tel.: (3822) 72-44-15

oalobacheva@sibmail.comAl'perinaE. L.АльперинаЕ. Л.
Russian Federation

PhD, Chief Scientific Worker, Laboratory of Neurochemical Modulation Mechanisms, Federal State Budget Institution Scientific Research Institute of Physiology, Siberian Department, Russian Academy of Medical Sciences. Address: 630117, Novosibirsk, Academician Timakov str. 4; Tel.: (383) 335-98-58

e.l.alperina@physiol.ruZhukovaE. N.ЖуковаЕ. Н.
Russian Federation

Candidate of Biological Sciences, Scientific Worker, Laboratory of Neurochemical Modulation Mechanisms, Federal State Budget Institution Scientific Research Institute of Physiology, Siberian Department, Russian Academy of Medical Sciences. Address: 630117, Novosibirsk, Academician Timakov str. 4; Tel.: (383) 335-98-58

maktub.9@mail.ruSemkeA. V.СемкеА. В.
Russian Federation

PhD, Professor, Head of Endogenic Disorders Department, Federal State Budget Institution Scientific Research Institute of Psychical Health, Siberian Department, Russian Academy of Medical Sciences. Address: 634014, Tomsk, Aleutskaya str. 4; Tel.: (3822) 72-31-51

asemke@mail.ruNikitinaV. B.НикитинаВ. Б.
Russian Federation

PhD, Leading Scientific Worker, Laboratory of Clinical Psychoneuroimmunology, Federal State Budget Institution Scientific Research Institute of psychical Health, Siberian Department, Russian Academy of Medical Sciences. Address: 634014, Tomsk, Aleutskaya str. 4; Tel.: (3822) 72-44-15

valentina08@sibmail.comCheidoM. A.ЧейдоМ. А.
Russian Federation

Candidate of Biological Sciences, Leading Scientific Worker, Laboratory of Neurochemical Modulation Mechanisms, Federal State Budget Institution Scientific Research Institute of Physiology, Siberian Department, Russian Academy of Medical Sciences. Address: 630117, Novosibirsk, Academician Timakov str. 4; Tel.: (383) 335-97-58

cheido@physiol.ruIdovaG. V.ИдоваГ. В.
Russian Federation

PhD, Professor, Head of Laboratory of Neurochemical Modulation Mechanisms, Federal State Budget Institution Scientific Research Institute of Physiology, Siberian Department, Russian Academy of Medical Sciences. Address: 630117, Novosibirsk, Academician Timakov str. 4; Tel.: (383) 335-97-58

galina@physiol.ruMental Health Research Institute under the Siberian Branch of the Russian Academy of Medical Sciences, Tomsk, Russian FederationMental Health Research Institute under the Siberian Branch of the Russian Academy of Medical Sciences, Tomsk, Russian FederationНаучно-исследовательский институт психического здоровья Сибирского отделения РАМН, Томск, Российская ФедерацияResearch Institute of Physiology under the Siberian Branch of the Russian Academy of Medical Sciences, Novosibirsk, Russian FederationНаучно-исследовательский институт физиологии Сибирского отделения РАМН, Новосибирск, Российская Федерация101220126712Вестник Российской академии медицинских наук131707082015Copyright ©; 2012, "Paediatrician" Publishers LLCCopyright ©; 2012, Издательство "Педиатръ"2012"Paediatrician" Publishers LLCИздательство "Педиатръ"https://vestnikramn.spr-journal.ru/jour/about/submissionshttps://vestnikramn.spr-journal.ru/jour/article/view/230

Study of immunomodulatory effect of atypical antipsychotic amisulpride has revealed a positive clinical effect after 6-week therapy of schizophrenic patients regarding both positive and negative symptoms. A decrease in activity of humoral immunity factors (В lymphocytes, immunoglobulins, HLA-DR+-cells) identified among schizophrenic patients in the process of amisulpride therapy can be attributed to a positive effect optimizing the ratio Th1/Th2. Amisulpride when used under experimental conditions produced a suppression of IgM-immune response in mice of the C57BL/6J strain. This effect was more expressed in animals with aggressive behavior pattern.

Изучение иммуномодулирующего эффекта атипичного антипсихотика амисульприда в клинике продемонстрировало положительный клинический эффект в динамике 6-недельной терапии больных шизофренией в отношении как позитивной, так и негативной симптоматики. Установленное снижение активности факторов гуморального иммунитета (В лимфоцитов, иммуноглобулинов, клеток HLA-DR+) у больных шизофренией в процессе терапии амисульпридом можно отнести к благоприятному эффекту, оптимизирующему соотношение Т лимфоцитов-хелперов Tх1/Tх2. Использование амисульприда в экспериментальных условиях привело к угнетению IgM-иммунного ответа у мышей линии С57BL/6J, наиболее выраженное при проявлении у них агрессивного типа поведения.

amisulprideschizophreniaC57BL/6J micecellular immunityhumoral immunityIgM-immune responseамисульпридшизофрениямыши линии С57BL/6Jклеточный иммунитетгуморальный иммунитетIgM-иммунный ответ1. Mosolov S.N., Ryvkin P.V., Serditov O.V., Ladyzhenskii M.Ya., Potapov A.V. Metabolic side effects of modern antipsychotic drug therapy. Sotsial'naya i klinicheskaya psikhiatriya = Social and clinical psychiatry. 2008; 3: 75–90.2. Gorobets L.N., Matrosova M.I., Shmukler A.B. Dynamics of clinical and endocrine, hormonal, biochemical, anthropometric and physical performance in patients with schizophrenia and schizophrenia spectrum disorders during treatment with sertindole. Sotsial'naya i klinicheskaya psikhiatriya = Social and clinical psychiatry. 2010; 20 (3): 59–67.3. Muller N., Schwarz M. Immunology in schizophrenic disorders. Nervenarzt. 2007; 78 (3): 253–256, 258–260, 262–263.4. Khaitov R.M., Pinegin B.V. Evaluation of the immune status of human health and disease. Immunologiya = Immunology. 2001; 4: 4–6.5. Kudryavtseva N.N., Bakshtanovskaya I.V. Neurochemical control of aggression and submission. Zhurn. vyssh.nervn. deyat. = Journal of Higher Nervous Activity. 1991; 41 (3): 459–466.6. Devoino L., Idova G., Alperina E., Cheido M. Brain neuromediator systems in the immune response control: pharmacological analysis of pre- and postsynaptic mechanisms. Brain Res. 1994; 633: 267–274.7. Seeman P. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2 (high) receptors. CNS Neurosci Ther. 2011; 17 (2): 118–132.8. Avedisova A.S., Yastrebov D.V. Amisulpride (Solian): The most atypical of atypical neuroleptics. Farmateka = Pharmateca. 2006; Spets. vypusk, 2: 2–6.9. Kryzhanovskii G.N., Magaeva S.V., Makarov S.P., Sepiashvili R.I. Neiroimmunopatologiya. Ruk-vo [Neuroimmunopathology. Manual]. Moscow, NII obshchei patologii i patofiziologii, 2003. 438 p.10. Devoino L.V., Idova G.V., Al'perina E.L. Psikhoneiroimmunomodulyatsiya: povedenie i immunitet. Rol' «neiromediatornoi ustanovki mozga [Psychoneuroimmunomodulation: Behavior and Immunity. The Role of "Brain Neurotransmitter Installation”]. Novosibirsk, Nauka, 2009. 167 p.11. Semke V.Ya., Vetlugina T.P., Nevidimova T.I., Ivanova S.A., Bokhan N.A. Klinicheskaya psikhoneiroimmunologiya [Clinical Psychoneuroimmunology]. Tomsk, RASKO, 2003. 300 p.12. Lobacheva O.A., Naidenova N.N., Vetlugina T.P. Cytokines in schizophrenia. Patogenez = Pathogenesis. 2006. 4 (1): 59–60.13. Vetlugina T.P., Nevidimova T.I.. Lobacheva O.A., Nikitina V.B. Tekhnologiya immunokorrektsii pri psikhicheskikh rasstroistvakh [Technology Immunomodulation in Mental Disorders]. Tomsk, Izd-vo Tom. un-ta. 2010. 172 p.14. Watanabe Y., Someya T., Nawa H.. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin. Neurosci. 2010. 64 (3): 217–230.15. Devoino L., Alperina E., Galkina O., Ilyutchenok R. Involvement of brain dopaminergic structures in neuroimmunomodulation. Intern. J. Neurosci. 1997; 91 (3–4): 213–228.16. Idova G.V., Alperna E.L., Cheido M.A. Contribution of brain dopamine, serotonin and opioid receptors in the mechanisms of neuroimmunomodulation: evidence from pharmacological analysis. Int. Immunopharmacol. 2012; 12 (4): 618–625.